Tuesday, 3 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Board Meeting Outcome

Cohance Lifesciences Board Meeting Outcome

Cohance Lifesciences approved the appointment of Mr. Umang Vohra as Chairman and Group CEO, succeeding Mr. Vivek Sharma who resigned effective April 30, 2026. The Board also approved the 'Cohance Lifesciences Limited – Employee Stock Option Plan, 2026' covering 2.59 crore options. These leadership transitions and incentive plans are subject to shareholder approval via postal ballot.

Source

NSE filing, NSE: COHANCE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Cohance Lifesciences Ltd: key numbers

Share price
₹440.35
Market cap
₹16,848 Cr
Revenue (annual)
₹2,269 Cr
Net profit (annual)
₹179.2 Cr
P/E (TTM)
158.6×Sector 41.3×
Promoter holding
57.48%-0.01% QoQ
FII holding
7.71%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Cohance Lifesciences Ltd

All →

Other board meeting outcome announcements

All →